The Belgian MIRA (MabThera In Rheumatoid Arthritis) registry: clues for the optimization of rituximab treatment strategies

Bert Vander Cruyssen,Patrick Durez,Rene Westhovens,Marie-Joëlle Kaiser,Ilse Hoffman,Filip De Keyser

The Belgian MIRA (MabThera In Rheumatoid Arthritis) registry: clues for the optimization of rituximab treatment strategies

2010

Bert Vander Cruyssen
Patrick Durez
Rene Westhovens
Marie-Joëlle Kaiser
Ilse Hoffman
Filip De Keyser

Introduction This study describes the results of the Belgian 'MabThera In Rheumatoid Arthritis (MIRA)' registry: effectiveness, safety and evaluation of the current retreatment practice on the background of the Belgian reimbursement criteria for rituximab.

Keywords:

TUMOR NECROSIS FACTOR BLOCKER
Immunology
Randomized controlled trial
Clinical Practice
Antirheumatic Agents
Rheumatoid arthritis
Rituximab
Reimbursement
Rheumatology
Internal medicine
Medicine
treatment strategy
treatment outcome

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations